Navigation Links
Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product
Date:6/17/2009

SALT LAKE CITY, June 17 /PRNewswire/ -- Great Basin Scientific, Inc., a privately held life sciences company developing novel, point-of-care molecular diagnostic solutions, today announced it has closed $3.6 million in bridge funding to support the company through 2009 and the launch of its first product, pending FDA 510(k) clearance in December. Returning investors participated in the funding round.

"With this round of financing we have secured all the funding needed for our entrance into the market as the second generation of diagnostic testing, a disruptive technology platform that promises accurate, point-of-care results and comes at a lower cost than the industry standard," said Ryan Ashton, president and CEO, Great Basin Scientific.

Successful Pre-clinical Study Completed

As part of the preparation for an August clinical trial for its first test- a 50 minute diagnostic test for Methicillin resistant Staphylococcus aureus (MRSA) from a positive blood culture, Great Basin Scientific is leading several pre-clinical studies. The company conducted a successful feasibility study last spring as it successfully characterized 132 retrospective samples from study collaborators at Children's Memorial Hospital in Chicago and Denver Health Hospital. Testing was performed at Great Basin Scientific's lab in Longmont, Colo.

"The results of the pre-clinical study completely met our expectations and keep us right on track as we approach clinical trials," said Rob Jenison, Great Basin Scientific's chief technology officer and vice president of development.

Beginning as early as mid-July, several major hospitals will serve as beta-testing sites for Great Basin Scientific's point of care molecular platform. During beta-testing, clinicians will test the analyzers and provide feedback on process flow and functionality. The testing will serve as preparation for the clinical trials scheduled to begin in August.

Future tests beyond hospital-acquired infections (HAIs)

In addition to its first product for MRSA testing, the company is also developing tests for Group B Streptococcus - the most common cause of sepsis and meningitis in newborns, and Human Papilloma Virus (HPV), the most common sexually transmitted infection of which certain types can lead to cervical cancer.

Great Basin Scientific's technology has several advantages over the traditional Polymerase Chain Reaction (PCR) method that requires the skills of highly-trained technicians and often times multiple rooms to avoid cross contamination of tests. Its automated, highly-sensitive, easy-to-use integrated cartridge system can be performed in a CLIA-rated moderately complex or waived laboratory, and will give healthcare providers and their patients the benefit of point-of-care test results within a 20 - 60 minute time frame at costs much lower than current molecular solutions. Other benefits include the ability to test for 32 distinct targets in a single assay and no batching of tests required.

About Great Basin Scientific

Great Basin Scientific, Inc. is a privately held life sciences company that commercializes breakthrough technologies for the molecular, rapid diagnostic testing market. The company is dedicated to development of simple yet powerful point-of-care technology and products that improve automation, throughput, scalability, reliability and ease of use of rapid diagnostic testing for point-of-care settings such as physician's office labs, small-medium hospital labs and other moderately complex laboratory facilities.

The company was founded in 2003 by David Ward, Ph.D., deputy director of the Nevada Cancer Institute, formerly of Yale University of Medicine, and Anthony R. Torres, M.D., senior scientist and director of the Immunogenetics Laboratory, Utah State University.

More information can be found on the company's Web site at www.gbscience.com.


'/>"/>
SOURCE Great Basin Scientific, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region
2. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
3. Newly Approved HIV Drug Shows Great Promise
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
6. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
7. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
8. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
9. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
10. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
11. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
Breaking Medicine Technology:
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... ... , ... There is no better place in South Florida to undergo two ... May issue of Consumer Reports focused on heart health. , The magazine gave ... after coronary bypass and aortic valve replacement procedures. , Consumer Reports rated ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
Breaking Medicine News(10 mins):